{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:40:45Z","timestamp":1789123245956,"version":"build-2803163510"},"reference-count":198,"publisher":"National Institute for Health and Care Research","issue":"17","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["14\/69\/01"],"award-info":[{"award-number":["14\/69\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In recent years, meters for continuous monitoring of interstitial fluid glucose have been introduced to help people with type 1 diabetes mellitus (T1DM) to achieve better control of their disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-2\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      The objective of this project was to summarise the evidence on the clinical effectiveness and cost-effectiveness of the MiniMed\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Paradigm\u2122 Veo system (Medtronic Inc., Northridge, CA, USA) and the Vibe\u2122 (Animas\n                      <jats:sup>\u00ae<\/jats:sup>\n                      Corporation, West Chester, PA, USA) and G4\n                      <jats:sup>\u00ae<\/jats:sup>\n                      PLATINUM CGM (continuous glucose monitoring) system (Dexcom Inc., San Diego, CA, USA) in comparison with multiple daily insulin injections (MDIs) or continuous subcutaneous insulin infusion (CSII), both with either self-monitoring of blood glucose (SMBG) or CGM, for the management of T1DM in adults and children.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-3\">\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>A systematic review was conducted in accordance with the principles of the Centre for Reviews and Dissemination guidance and the National Institute for Health and Care Excellence Diagnostic Assessment Programme manual. We searched 14 databases, three trial registries and two conference proceedings from study inception up to September 2014. In addition, reference lists of relevant systematic reviews were checked. In the absence of randomised controlled trials directly comparing Veo or an integrated CSII\u2009+\u2009CGM system, such as Vibe, with comparator interventions, indirect treatment comparisons were performed if possible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-4\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A commercially available cost-effectiveness model, the IMS Centre for Outcomes Research and Effectiveness diabetes model version 8.5 (IMS Health, Danbury, CT, USA), was used for this assessment. This model is an internet-based, interactive simulation model that predicts the long-term health outcomes and costs associated with the management of T1DM and type 2 diabetes. The model consists of 15 submodels designed to simulate diabetes-related complications, non-specific mortality and costs over time. As the model simulates individual patients over time, it updates risk factors and complications to account for disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-5\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-four publications resulting from 19 studies were included in the review. Overall, the evidence suggests that the Veo system reduces hypoglycaemic events more than other treatments, without any differences in other outcomes, including glycated haemoglobin (HbA\n                      <jats:sub>1c<\/jats:sub>\n                      ) levels. We also found significant results in favour of the integrated CSII\u2009+\u2009CGM system over MDIs with SMBG with regard to HbA\n                      <jats:sub>1c<\/jats:sub>\n                      levels and quality of life. However, the evidence base was poor. The quality of the included studies was generally low, often with only one study comparing treatments in a specific population at a specific follow-up time. In particular, there was only one study comparing Veo with an integrated CSII\u2009+\u2009CGM system and only one study comparing Veo with a CSII\u2009+\u2009SMBG system in a mixed population. Cost-effectiveness analyses indicated that MDI\u2009+\u2009SMBG is the option most likely to be cost-effective, given the current threshold of \u00a330,000 per quality-adjusted life-year gained, whereas integrated CSII\u2009+\u2009CGM systems and Veo are dominated and extendedly dominated, respectively, by stand-alone, non-integrated CSII with CGM. Scenario analyses did not alter these conclusions. No cost-effectiveness modelling was conducted for children or pregnant women.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-6\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Veo system does appear to be better than the other systems considered at reducing hypoglycaemic events. However, in adults, it is unlikely to be cost-effective. Integrated systems are also generally unlikely to be cost-effective given that stand-alone systems are cheaper and, possibly, no less effective. However, evidence in this regard is generally lacking, in particular for children. Future trials in specific child, adolescent and adult populations should include longer term follow-up and ratings on the European Quality of Life-5 Dimensions scale at various time points with a view to informing improved cost-effectiveness modelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-7\">\n                    <jats:title>Study registration<\/jats:title>\n                    <jats:p>PROSPERO Registration Number CRD42014013764.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-8\">\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>The National Institute for Health Research Health Technology Assessment programme.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3310\/hta20170","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T04:36:16Z","timestamp":1456979776000},"page":"1-252","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":54,"title":["Integrated sensor-augmented pump therapy systems [the MiniMed\u00ae Paradigm\u2122 Veo system and the Vibe\u2122 and G4\u00ae PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation"],"prefix":"10.3310","volume":"20","author":[{"given":"Rob","family":"Riemsma","sequence":"first","affiliation":[{"name":"Kleijnen Systematic Reviews Ltd, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Corro Ramos","sequence":"additional","affiliation":[{"name":"Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Birnie","sequence":"additional","affiliation":[{"name":"Kleijnen Systematic Reviews Ltd, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasuh","family":"B\u00fcy\u00fckkaramikli","sequence":"additional","affiliation":[{"name":"Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Kleijnen Systematic Reviews Ltd, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Ryder","sequence":"additional","affiliation":[{"name":"Kleijnen Systematic Reviews Ltd, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Duffy","sequence":"additional","affiliation":[{"name":"Kleijnen Systematic Reviews Ltd, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Worthy","sequence":"additional","affiliation":[{"name":"Kleijnen Systematic Reviews Ltd, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiwenn","family":"Al","sequence":"additional","affiliation":[{"name":"Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Severens","sequence":"additional","affiliation":[{"name":"Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Kleijnen","sequence":"additional","affiliation":[{"name":"Kleijnen Systematic Reviews Ltd, York, UK"},{"name":"School for Public Health and Primary Care, Maastricht University, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2016,2]]},"reference":[{"key":"key20160301161136741_ref1-bib1","volume-title":"Type 1 Diabetes: Diagnosis And Management of Type 1 Diabetes in Adults. Final Scope","author":"National Institute for Health and Care Excellence","year":"2012"},{"key":"key20160301161136741_ref1-bib2","volume-title":"Diabetes","author":"NHS Choices","year":"2012"},{"key":"key20160301161136741_ref1-bib3","volume-title":"Diabetes Prevalence Model (APHO)","author":"Yorkshire and Humber Health Intelligence","year":"2010"},{"key":"key20160301161136741_ref1-bib4","volume-title":"Clinical Knowledge Summaries. Diabetes \u2013 Type 1","author":"National Institute for Health and Care Excellence","year":"2012"},{"key":"key20160301161136741_ref1-bib5","volume-title":"Type 2 Diabetes: Management of Type 2 Diabetes in Adults. Final Scope","author":"National Institute for Health and Care Excellence","year":"2012"},{"key":"key20160301161136741_ref1-bib6","volume-title":"What is the Optimal Blood Glucose (Sugar) Range?","author":"Juvenile Diabetes Research Foundation Ltd"},{"key":"key20160301161136741_ref1-bib7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"key20160301161136741_ref1-bib8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"key":"key20160301161136741_ref1-bib9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S0272-6386(99)70035-1","article-title":"End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions","volume":"34","author":"Ritz","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"key20160301161136741_ref1-bib10","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1001\/jama.290.15.2057","article-title":"Important causes of visual impairment in the world today","volume":"290","author":"Congdon","year":"2003","journal-title":"JAMA"},{"key":"key20160301161136741_ref1-bib11","volume-title":"State of the Nation 2012: England","author":"Diabetes UK","year":"2012"},{"key":"key20160301161136741_ref1-bib12","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/j.1464-5491.2006.01962.x","article-title":"A longitudinal observational study of insulin therapy and glycaemic control in Scottish children with type 1 diabetes: DIABAUD 3","volume":"23","author":"Scottish Study Group for the Care of the Young with Diabetes","year":"2006","journal-title":"Diabet Med"},{"key":"key20160301161136741_ref1-bib13","volume-title":"National Paediatric Diabetes Audit Report 2011\u201312. Part 1 Care Processes and Outcomes","author":"National Paediatric Diabetes Audit Project Board","year":"2013"},{"key":"key20160301161136741_ref1-bib14","volume-title":"Continuous Subcutaneous Insulin Infusion for the Treatment of Diabetes Mellitus. NICE Technology Appraisal Guidance 151","author":"National Institute for Health and Care Excellence"},{"key":"key20160301161136741_ref1-bib15","first-page":"2","article-title":"Sudden death and hypoglycaemia","volume":"1","author":"Heller","year":"2008","journal-title":"Diabetic Hypoglycemia"},{"key":"key20160301161136741_ref1-bib16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-2431-10-50","article-title":"Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review","volume":"10","author":"Barnard","year":"2010","journal-title":"BMC Pediatr"},{"key":"key20160301161136741_ref1-bib17","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1136\/bmj.325.7367.746","article-title":"Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial","volume":"325","author":"DAFNE Study Group","year":"2002","journal-title":"BMJ"},{"key":"key20160301161136741_ref1-bib18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1089\/dia.2011.0201","article-title":"Psychosocial correlates of continuous glucose monitoring use in youth and adults with type 1 diabetes and parents of youth","volume":"14","author":"Markowitz","year":"2012","journal-title":"Diabetes Technol Ther"},{"key":"key20160301161136741_ref1-bib19","doi-asserted-by":"publisher","first-page":"e000025","DOI":"10.1136\/bmjdrc-2014-000025","article-title":"Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents","volume":"2","author":"Barnard","year":"2014","journal-title":"BMJ Open Diab Res Care"},{"key":"key20160301161136741_ref1-bib20","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.2337\/dc10-2411","article-title":"Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk","volume":"34","author":"Choudhary","year":"2011","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib21","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1001\/jama.2013.278576","article-title":"Insulin pump therapy with automated insulin suspension: toward freedom from nocturnal hypoglycemia","volume":"310","author":"Choudhary","year":"2013","journal-title":"JAMA"},{"key":"key20160301161136741_ref1-bib22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/193229681300700408","article-title":"Susceptibility of interstitial continuous glucose monitor performance to sleeping position","volume":"7","author":"Mensh","year":"2013","journal-title":"J Diabetes Sci Technol"},{"key":"key20160301161136741_ref1-bib23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0168-8227(11)70025-0","article-title":"Insulin pump therapy in adults","volume":"93","author":"Didangelos","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"key20160301161136741_ref1-bib24","volume-title":"Systematic Reviews: CRD\u2019s Guidance for Undertaking Reviews in Health Care","author":"Centre for Reviews and Dissemination","year":"2009"},{"key":"key20160301161136741_ref1-bib25","volume-title":"Diagnostics Assessment Programme Manual","author":"National Institute for Health and Clinical Excellence","year":"2011"},{"key":"key20160301161136741_ref1-bib26","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [Updated March 2011]","author":"Higgins","year":"2011"},{"key":"key20160301161136741_ref1-bib27","volume-title":"CADTH Peer Review Checklist for Search Strategies","author":"Canadian Agency for Drugs and Technologies in Health","year":"2013"},{"key":"key20160301161136741_ref1-bib28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"key20160301161136741_ref1-bib29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"key20160301161136741_ref1-bib30","doi-asserted-by":"publisher","first-page":"b1147","DOI":"10.1136\/bmj.b1147","article-title":"Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews","volume":"338","author":"Song","year":"2009","journal-title":"BMJ"},{"key":"key20160301161136741_ref1-bib31","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"key20160301161136741_ref1-bib32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1303576","article-title":"Threshold-based insulin-pump interruption for reduction of hypoglycemia","volume":"369","author":"Bergenstal","year":"2013","journal-title":"N Engl J Med"},{"key":"key20160301161136741_ref1-bib33","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/jama.2013.277818","article-title":"Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial","volume":"310","author":"Ly","year":"2013","journal-title":"JAMA"},{"key":"key20160301161136741_ref1-bib34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1089\/dia.2008.0068","article-title":"Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study","volume":"10","author":"Hirsch","year":"2008","journal-title":"Diabetes Technol Ther"},{"key":"key20160301161136741_ref1-bib35","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1007\/s00125-009-1365-0","article-title":"Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial","volume":"52","author":"O\u2019Connell","year":"2009","journal-title":"Diabetologia"},{"key":"key20160301161136741_ref1-bib36","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2337\/dc09-0750","article-title":"Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study","volume":"32","author":"Raccah","year":"2009","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib37","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/j.1464-5491.2011.03256.x","article-title":"Sensor-augmented pump therapy lowers HbA1c in suboptimally controlled type 1 diabetes; a randomized controlled trial","volume":"28","author":"Hermanides","year":"2011","journal-title":"Diabet Med"},{"key":"key20160301161136741_ref1-bib38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1177\/193229680700100313","article-title":"Combined insulin pump therapy with real-time continuous glucose monitoring significantly improves glycemic control compared to multiple daily injection therapy in pump naive patients with type 1 diabetes; single center pilot study experience","volume":"1","author":"Lee","year":"2007","journal-title":"J Diabetes Sci Technol"},{"key":"key20160301161136741_ref1-bib39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/dia.2008.0002","article-title":"Patient-reported outcomes for an integrated real-time continuous glucose monitoring\/insulin pump system","volume":"11","author":"Peyrot","year":"2009","journal-title":"Diabetes Technol Ther"},{"key":"key20160301161136741_ref1-bib40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1002853","article-title":"Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes","volume":"363","author":"Bergenstal","year":"2010","journal-title":"N Engl J Med"},{"key":"key20160301161136741_ref1-bib41","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2337\/dc08-1874","article-title":"Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study","volume":"32","author":"Bolli","year":"2009","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib42","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.2337\/diacare.25.11.2074","article-title":"A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control","volume":"25","author":"DeVries","year":"2002","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib43","first-page":"289","article-title":"Frequency of hypoglycaemic and hyperglycaemic-ketotic episodes during conventional and subcutaneous continuous insulin infusion therapy in IDDM","volume":"1","author":"Nosadini","year":"1988","journal-title":"Diabetes Nutr Metab"},{"key":"key20160301161136741_ref1-bib44","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/0002-9394(85)90618-X","article-title":"Effects of intensified insulin treatment on various lesions of diabetic retinopathy","volume":"100","author":"Brinchmann-Hansen","year":"1985","journal-title":"Am J Ophthalmol"},{"key":"key20160301161136741_ref1-bib45","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/j.1464-5491.2007.02196.x","article-title":"A randomized pilot study in type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone","volume":"24","author":"Thomas","year":"2007","journal-title":"Diabet Med"},{"key":"key20160301161136741_ref1-bib46","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.2337\/diacare.24.10.1722","article-title":"Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection","volume":"24","author":"Tsui","year":"2001","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib47","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1542\/peds.112.3.559","article-title":"Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial","volume":"112","author":"Weintrob","year":"2003","journal-title":"Pediatrics"},{"key":"key20160301161136741_ref1-bib48","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1089\/dia.2011.0085","article-title":"Insulin pump therapy started at the time of diagnosis: effects on glycemic control and pancreatic beta-cell function in type 1 diabetes","volume":"13","author":"Thrailkill","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"key20160301161136741_ref1-bib49","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.2337\/diacare.27.7.1554","article-title":"A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine","volume":"27","author":"Doyle","year":"2004","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib50","first-page":"33","article-title":"Is continuous subcutaneous insulin infusion more effective than intensive conventional insulin therapy in the treatment of pregnant diabetic women?","volume":"6","author":"Nosari","year":"1993","journal-title":"Diabetes Nutr Metab"},{"key":"key20160301161136741_ref1-bib51","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/1471-2431-14-183","article-title":"The JDRF CCTN CGM TIME trial: Timing of Initiation of continuous glucose Monitoring in Established pediatric type 1 diabetes: study protocol, recruitment and baseline characteristics","volume":"14","author":"Lawson","year":"2014","journal-title":"BMC Pediatr"},{"key":"key20160301161136741_ref1-bib52","first-page":"A135","article-title":"The ASPIRE-2 Study of Automatic Insulin Suspension: Design, Methods, and Interim Baseline Characteristics. Paper presented at the 12th annual Diabetes Technology Meeting, 8\u201310 November 2012, Bethesda, USA, abstract no. 135","volume":"7","author":"Troub","year":"2013","journal-title":"J Diabetes Sci Technol"},{"key":"key20160301161136741_ref1-bib53","article-title":"Randomised Controlled Trial of Continuous Subcutaneous Insulin Infusion Compared to Multiple Daily Injection Regimens in Children and Young People at Diagnosis of Type I Diabetes Mellitus","author":"Blair","year":"2010"},{"key":"key20160301161136741_ref1-bib54","volume-title":"Study of Insulin Therapy Augmented by Real Time Sensor in Type 1 Children and Adolescents (START-IN!)","author":"Assistance Publique \u2013 H\u00f4pitaux de Paris","year":"2012"},{"key":"key20160301161136741_ref1-bib55","volume-title":"Effect of CSII and CGM on Progression of Late Diabetic Complications","author":"Steen Andersen","year":"2011"},{"key":"key20160301161136741_ref1-bib56","volume-title":"Threshold Suspend in Pediatrics at Home","author":"Medtronic Diabetes","year":"2014"},{"key":"key20160301161136741_ref1-bib57","volume-title":"CGM Treatment in Patients with Type 1 Diabetes Treated with Insulin Injections","author":"Vastra Gotaland Region","year":"2014"},{"key":"key20160301161136741_ref1-bib58","volume-title":"Comparison of Insulin Pump and MDI for Pregestational Diabetes During Pregnancy","author":"University of British Columbia","year":"2014"},{"key":"key20160301161136741_ref1-bib59","volume-title":"The REPOSE (Relative Effectiveness of Pumps Over MDI and Structured Education) Trial","author":"Sheffield Teaching Hospitals NHS Foundation Trust","year":"2011"},{"key":"key20160301161136741_ref1-bib60","volume-title":"The Effectiveness of Continuous Glucose Monitoring in Diabetes Treatment for Infants and Young Children (Gerber RTSA)","author":"Seattle Children\u2019s Hospital","year":"2011"},{"key":"key20160301161136741_ref1-bib61","volume-title":"Insulin Pump Therapy in Adolescents with Newly Diagnosed Type 1 Diabetes (T1D)","author":"Larry Fox","year":"2015"},{"key":"key20160301161136741_ref1-bib62","volume-title":"A Randomised Controlled Study of Continuous Subcutaneous Insulin Infusion (CSII) Therapy Compared to Conventional Bolus Insulin Treatment in Preschool Aged Children with Type 1 Diabetes","author":"Addenbrooke\u2019s NHS Trust","year":"2006"},{"key":"key20160301161136741_ref1-bib63","volume-title":"Does Real-Time Patient Analysis of Continuous Glucose Monitor Data Improve Glycaemic Control in Patients with Type 1 Diabetes on Insulin Pump Therapy?","author":"Medtronic Australasia","year":"2006"},{"key":"key20160301161136741_ref1-bib64","volume-title":"Predictive Low Glucose Management (PLGM) Trial: Comparing Insulin Pump Therapy with Predictive Low Glucose Suspend Feature Versus Standard Sensor Augmented Pump Therapy in Patients with Type 1 Diabetes","author":"Juvenile Diabetes Research Foundation","year":"2014"},{"key":"key20160301161136741_ref1-bib65","volume-title":"A Randomized Controlled Trial Comparing the Impact of Continuous Subcutaneous Insulin Infusion (CSII) Therapy and Multiple Daily Injection (MDI) Regimens upon Indices of Behaviour, Cognition and Glycaemia in Children and Adolescents with Type 1 Diabetes","author":"The Royal Children\u2019s Hospital Melbourne","year":"2010"},{"key":"key20160301161136741_ref1-bib66","volume-title":"Integrated Blood Glucose Monitoring with Insulin Pumps Versus Standard Method \u2013 A Randomised Crossover Trial","author":"Royal Children\u2019s Hospital","year":"2011"},{"key":"key20160301161136741_ref1-bib67","volume-title":"SCIPI-Subcutaneous Insulin: Pumps or Injections","author":"Alder Hey Children\u2019s NHS Foundation Trust","year":"2010"},{"key":"key20160301161136741_ref1-bib68","volume-title":"Psychosocial Issues in Insulin Pump Therapy in Children with Type 1 DM","author":"University of Schleswig-Holstein","year":"2011"},{"key":"key20160301161136741_ref1-bib69","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jval.2012.02.011","article-title":"Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States","volume":"15","author":"Kamble","year":"2012","journal-title":"Value Health"},{"key":"key20160301161136741_ref1-bib70","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jval.2014.05.008","article-title":"A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes","volume":"17","author":"Ly","year":"2014","journal-title":"Value Health"},{"key":"key20160301161136741_ref1-bib71","doi-asserted-by":"publisher","first-page":"A82","DOI":"10.1016\/j.jval.2011.02.458","article-title":"The cost-effectiveness of initiating sensor-augmented pump therapy versus multiple daily injections of insulin in adults with type 1 diabetes: evaluating a technology in evolution. Paper presented at the 16th annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 21\u201325 May 2011, Baltimore, USA, abstract no. 82","volume":"14","author":"Kamble","year":"2011","journal-title":"Value Health"},{"key":"key20160301161136741_ref1-bib72","first-page":"A67","article-title":"Clinical impact of sensor-augmented insulin pump (SAP) therapy in type 1 diabetes long-term related complications in Colombia. Paper presented at the 7th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), 5\u20138 February 2014, Vienna, Austria","volume":"16","author":"Gomez","year":"2014","journal-title":"Diabetes Technol Ther"},{"key":"key20160301161136741_ref1-bib73","doi-asserted-by":"publisher","first-page":"A690","DOI":"10.1016\/j.jval.2013.08.2059","article-title":"Health economic benefits of sensor augmented insulin pump therapy in Colombia. Paper presented at ISPOR 4th Latin America Conference, 12\u201314 September 2013, Buenos Aires, Argentina","volume":"16","author":"Gomez","year":"2013","journal-title":"Value Health"},{"key":"key20160301161136741_ref1-bib74","first-page":"A74","article-title":"CGM and SAP are valuable tools in the treatment of diabetes: a Swedish health technology assessment. Paper presented at the 7th International Conference on Advanced Technologies and Treatments for Diabetes, 5\u20138 February 2014, Vienna, Austria","volume":"16","author":"Lindholm Olinder","year":"2014","journal-title":"Diabetes Technol Ther"},{"key":"key20160301161136741_ref1-bib75","first-page":"A348","article-title":"Projection of long term health-economic benefits of sensor augmented pump (SAP) versus pump therapy alone (CSII) in uncontrolled type 1 diabetes in France. Paper presented at ISPOR 17th Annual European Congress, 8\u201312 November 2014, Amsterdam, the Netherlands","volume":"17","author":"Roze","year":"2014","journal-title":"Value Health"},{"key":"key20160301161136741_ref1-bib76","first-page":"A348","article-title":"Projection of long term health-economic benefits of sensor augmented pump (SAP) versus pump therapy alone (CSII) in type 1 diabetes, a UK perspective. Paper presented at ISPOR 17th Annual European Congress, 8\u201312 November 2014, Amsterdam, the Netherlands","volume":"17","author":"Roze","year":"2014","journal-title":"Value Health"},{"key":"key20160301161136741_ref1-bib77","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","article-title":"Guidelines for authors and peer reviewers of economic submissions to the BMJ","volume":"313","author":"Drummond","year":"1996","journal-title":"BMJ"},{"key":"key20160301161136741_ref1-bib78","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jval.2014.03.003","article-title":"Review of utility values for economic modeling in type 2 diabetes","volume":"17","author":"Beaudet","year":"2014","journal-title":"Value Health"},{"key":"key20160301161136741_ref1-bib79","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1185\/030079904X1980","article-title":"The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making","volume":"20","author":"Palmer","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"key20160301161136741_ref1-bib80","doi-asserted-by":"publisher","DOI":"10.3310\/hta14110","article-title":"Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation","volume":"14","author":"Cummins","year":"2010","journal-title":"Health Technol Assess"},{"key":"key20160301161136741_ref1-bib81","volume-title":"Type 1 Diabetes in Adults: Diagnosis and Management. NICE Guideline (NG17)","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"key20160301161136741_ref1-bib82","volume-title":"Dapagliflozin in Combination Therapy for Treating Type 2 Diabetes. NICE Technology Appraisal Guidance 288","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"key20160301161136741_ref1-bib83","volume-title":"Liraglutide for the Treatment of Type 2 Diabetes Mellitus. NICE Technology Appraisal Guidance 203","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"key20160301161136741_ref1-bib84","volume-title":"Exenatide Prolonged-Release Suspension for Injection in Combination with Oral Antidiabetic Therapy for the Treatment of Type 2 Diabetes. NICE Technology Appraisal Guidance 248","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"key20160301161136741_ref1-bib85","volume-title":"Canagliflozin in Combination Therapy for Treating Type 2 Diabetes. NICE technology appraisal guidance 315","author":"National Institute for Health and Care Excellence"},{"key":"key20160301161136741_ref1-bib86","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc07-9919","article-title":"Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting","volume":"30","author":"The Mount Hood 4 Modeling Group","year":"2007","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib87","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0168-8227(00)00217-5","article-title":"The Mt. Hood challenge: cross-testing two diabetes simulation models","volume":"50","author":"Brown","year":"2000","journal-title":"Diabetes Res Clin Pract"},{"key":"key20160301161136741_ref1-bib88","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jval.2013.01.002","article-title":"Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting","volume":"16","author":"Palmer","year":"2013","journal-title":"Value Health"},{"key":"key20160301161136741_ref1-bib89","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1185\/030079904X2006","article-title":"Validation of the CORE Diabetes Model against epidemiological and clinical studies","volume":"20","author":"Palmer","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"key20160301161136741_ref1-bib90","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jval.2014.07.007","article-title":"Validation of the IMS CORE Diabetes Model","volume":"17","author":"McEwan","year":"2014","journal-title":"Value Health"},{"key":"key20160301161136741_ref1-bib91","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","article-title":"A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)","volume":"47","author":"Clarke","year":"2004","journal-title":"Diabetologia"},{"key":"key20160301161136741_ref1-bib92","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.2337\/diab.45.10.1289","article-title":"The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial","volume":"45","year":"1996","journal-title":"Diabetes"},{"key":"key20160301161136741_ref1-bib93","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0002-8703(00)90236-9","article-title":"Primary and subsequent coronary risk appraisal: new results from the Framingham study","volume":"139","author":"D\u2019Agostino","year":"2000","journal-title":"Am Heart J"},{"key":"key20160301161136741_ref1-bib94","volume-title":"WHO Mortality Database","author":"World Health Organization","year":"2014"},{"key":"key20160301161136741_ref1-bib95","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/archinte.159.11.1197","article-title":"Profile for estimating risk of heart failure","volume":"159","author":"Kannel","year":"1999","journal-title":"Arch Intern Med"},{"key":"key20160301161136741_ref1-bib96","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1161\/01.STR.0000020091.07144.C7","article-title":"UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine","volume":"33","author":"Kothari","year":"2002","journal-title":"Stroke"},{"key":"key20160301161136741_ref1-bib97","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/01.CIR.96.1.44","article-title":"Intermittent claudication. A risk profile from The Framingham Heart Study","volume":"96","author":"Murabito","year":"1997","journal-title":"Circulation"},{"key":"key20160301161136741_ref1-bib98","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1042\/cs1010671","article-title":"The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56)","volume":"101","author":"Stevens","year":"2001","journal-title":"Clin Sci (Lond)"},{"key":"key20160301161136741_ref1-bib99","volume-title":"National Diabetes Audit 2011\u20132012. Report 1: Care Processes and Treatment Targets","author":"Health and Social Care Information Centre","year":"2013"},{"key":"key20160301161136741_ref1-bib100","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/archinternmed.2009.193","article-title":"Modern-day clinical course of type 1 diabetes mellitus after 30 years\u2019 duration: the diabetes control and complications trial\/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983\u20132005)","volume":"169","author":"Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications (DCCT\/EDIC) Research Group","year":"2009","journal-title":"Arch Intern Med"},{"key":"key20160301161136741_ref1-bib101","volume-title":"Opinions and Lifestyle Survey, Smoking Habits Amongst Adults, 2012","author":"Office for National Statistics","year":"2013"},{"key":"key20160301161136741_ref1-bib102","volume-title":"Global Status Report on Alcohol and Health","author":"World Health Organization","year":"2011"},{"key":"key20160301161136741_ref1-bib103","volume-title":"Health Survey for England, 2011. Volume 1: Health, Social Care and Lifestyles: Cardiovascular Disease","author":"Health and Social Care Information Centre","year":"2011"},{"key":"key20160301161136741_ref1-bib104","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc11-1579","article-title":"Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience","volume":"35","author":"Hopkins","year":"2012","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib105","volume-title":"Unit Costs of Health and Social Care","author":"Personal Social Services Research Unit (PSSRU)"},{"key":"key20160301161136741_ref1-bib106","volume-title":"Electronic Drug Tariff","author":"NHS Business Services Authority","year":"2014"},{"key":"key20160301161136741_ref1-bib107","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1258\/acb.2009.009007","article-title":"How should proteinuria be detected and measured?","volume":"46","author":"Lamb","year":"2009","journal-title":"Ann Clin Biochem"},{"key":"key20160301161136741_ref1-bib108","volume-title":"NHS reference costs 2012\u20132013","author":"Department of Health","year":"2013"},{"key":"key20160301161136741_ref1-bib109","volume-title":"Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. NICE Guideline (CG181)","author":"National Institute for Health and Care Excellence","year":"2014"},{"key":"key20160301161136741_ref1-bib110","volume-title":"Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. Clinical Guideline: Methods, Evidence and Recommendations; July 2014","author":"National Clinical Guideline Centre","year":"2014"},{"key":"key20160301161136741_ref1-bib111","volume-title":"Peritoneal Dialysis: Peritoneal Dialysis in the Treatment of Stage 5 Chronic Kidney Disease. NICE Clinical Guideline 125","author":"National Institute for Health and Care Excellence","year":"2011"},{"key":"key20160301161136741_ref1-bib112","volume-title":"Glaucoma: Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension. NICE clinical guideline 85","author":"National Institute for Health and Care Excellence","year":"2009"},{"key":"key20160301161136741_ref1-bib113","volume-title":"Glaucoma: Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension. Methods, Evidence and Recommendations","author":"National Collaborating Centre for Acute Care","year":"2009"},{"key":"key20160301161136741_ref1-bib114","volume-title":"Duloxetine","author":"Monthly Index of Medical Specialties","year":"2014"},{"key":"key20160301161136741_ref1-bib115","volume-title":"Neuropathic Pain: the Pharmacological Management of Neuropathic Pain in Adults in Non-Specialist Settings. NICE Clinical Guideline 96","author":"National Institute for Health and Care Excellence","year":"2010"},{"key":"key20160301161136741_ref1-bib116","volume-title":"Lower Limb Peripheral Arterial Disease: Diagnosis and Management. NICE Clinical Guideline 147","author":"National Institute for Health and Care Excellence","year":"2012"},{"key":"key20160301161136741_ref1-bib117","volume-title":"Lower Limb Peripheral Arterial Disease: Diagnosis and Management. NICE Clinical Guideline; Methods, Evidence and Recommendations. Draft for Consultation","author":"National Clinical Guideline Centre","year":"2012"},{"key":"key20160301161136741_ref1-bib118","doi-asserted-by":"publisher","first-page":"70","DOI":"10.12968\/jowc.2002.11.2.26675","article-title":"Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries","volume":"11","author":"Ghatnekar","year":"2002","journal-title":"J Wound Care"},{"key":"key20160301161136741_ref1-bib119","volume-title":"Foot Care for People with Diabetes: the Economic Case for Change","author":"Kerr","year":"2012"},{"key":"key20160301161136741_ref1-bib120","volume-title":"Comparative Table of Insulin Pumps","author":"London New Drugs Group","year":"2013"},{"key":"key20160301161136741_ref1-bib121","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.1111\/dme.12325","article-title":"The U.K. service level audit of insulin pump therapy in adults","volume":"31","author":"White","year":"2014","journal-title":"Diabet Med"},{"key":"key20160301161136741_ref1-bib122","volume-title":"The United Kingdom Insulin Pump Audit \u2013 Service Level Data","author":"Diabetes UK","year":"2013"},{"key":"key20160301161136741_ref1-bib123","volume-title":"Prescription Cost Analysis \u2013 England, 2012 [NS]","author":"Health and Social Care Information Centre","year":"2013"},{"key":"key20160301161136741_ref1-bib124","volume-title":"National Tariff Payment System 2014\/15","author":"Monitor, NHS England","year":"2013"},{"key":"key20160301161136741_ref1-bib125","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/MLR.0b013e318234a04a","article-title":"Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods","volume":"50","author":"Ara","year":"2012","journal-title":"Med Care"},{"key":"key20160301161136741_ref1-bib126","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/027298902400448902","article-title":"Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62)","volume":"22","author":"Clarke","year":"2002","journal-title":"Med Decis Making"},{"key":"key20160301161136741_ref1-bib127","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1185\/030079906X115757","article-title":"Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes","volume":"22","author":"Currie","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"key20160301161136741_ref1-bib128","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.2337\/diacare.27.5.1066","article-title":"Diabetes, depression, and quality of life: a population study","volume":"27","author":"Goldney","year":"2004","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib129","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1524-4733.2007.00211.x","article-title":"Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus","volume":"11","author":"Minshall","year":"2008","journal-title":"Value Health"},{"key":"key20160301161136741_ref1-bib130","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N Engl J Med"},{"key":"key20160301161136741_ref1-bib131","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s00134-004-2242-4","article-title":"Glycemic control in the ICU: a multicenter survey","volume":"30","author":"McMullin","year":"2004","journal-title":"Intensive Care Med"},{"key":"key20160301161136741_ref1-bib132","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/01.WON.0000341471.41191.18","article-title":"The case for evidence in wound care: investigating advanced treatment modalities in healing chronic diabetic lower extremity wounds","volume":"35","author":"Lyon","year":"2008","journal-title":"J Wound Ostomy Continence Nurs"},{"key":"key20160301161136741_ref1-bib133","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.2337\/dc07-0350","article-title":"Depression screening disparities among veterans with diabetes compared with the general veteran population","volume":"30","author":"Jones","year":"2007","journal-title":"Diabetes Care"},{"issue":"21","key":"key20160301161136741_ref1-bib134","article-title":"Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration","volume":"4","author":"O\u2019Meara","year":"2000","journal-title":"Health Technol Assess"},{"key":"key20160301161136741_ref1-bib135","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/00042728-200104000-00005","article-title":"Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis","volume":"27","author":"Kantor","year":"2001","journal-title":"Dermatol Surg"},{"key":"key20160301161136741_ref1-bib136","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1464-5491.2007.02074.x","article-title":"Sensitivity and specificity of digital retinal imaging for screening diabetic retinopathy","volume":"24","author":"Lopez-Bastida","year":"2007","journal-title":"Diabet Med"},{"key":"key20160301161136741_ref1-bib137","first-page":"190","article-title":"Utility of the Dipstick Micraltest II in the screening of microalbuminuria of diabetes mellitus type 2 and essential hypertension","volume":"58","author":"Cortes-Sanabria","year":"2006","journal-title":"Rev Invest Clin"},{"key":"key20160301161136741_ref1-bib138","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1056\/NEJMoa066397","article-title":"Long-term effect of diabetes and its treatment on cognitive function","volume":"356","author":"Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications Study Research Group","year":"2007","journal-title":"N Engl J Med"},{"key":"key20160301161136741_ref1-bib139","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2337\/diab.46.2.271","article-title":"Hypoglycemia in the Diabetes Control and Complications Trial","volume":"46","author":"The Diabetes Control and Complications Trial Research Group","year":"1997","journal-title":"Diabetes"},{"key":"key20160301161136741_ref1-bib140","first-page":"S432","article-title":"Routine use of personal continuous glucose monitoring system with insulin pump in Sweden. Paper presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD), 1\u20135 October 2012, Berlin, Germany","volume":"55","author":"Lynch","year":"2012","journal-title":"Diabetologia"},{"key":"key20160301161136741_ref1-bib141","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1136\/bmj.293.6556.1195","article-title":"Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study","volume":"293","author":"Dahl-Jorgensen","year":"1986","journal-title":"Br Med J"},{"key":"key20160301161136741_ref1-bib142","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/archinte.159.3.281","article-title":"Drug-induced hypoglycemic coma in 102 diabetic patients","volume":"159","author":"Ben-Ami","year":"1999","journal-title":"Arch Intern Med"},{"key":"key20160301161136741_ref1-bib143","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2337\/diacare.10.5.617","article-title":"Fear of hypoglycemia: quantification, validation, and utilization","volume":"10","author":"Cox","year":"1987","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib144","doi-asserted-by":"crossref","first-page":"369","DOI":"10.5694\/j.1326-5377.1995.tb139941.x","article-title":"The Diabetes Control and Complications Trial. Implications for children and adolescents. Australasian Paediatric Endocrine Group","volume":"162","author":"Couper","year":"1995","journal-title":"Med J Aust"},{"key":"key20160301161136741_ref1-bib145","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2337\/diacare.10.4.510","article-title":"Intellectual deficits associated with early onset of insulin dependent diabetes mellitus in children","volume":"10","author":"Rovet","year":"1987","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib146","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0022-3476(94)70190-3","article-title":"Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial","volume":"125","author":"Diabetes Control and Complications Trial Research Group","year":"1994","journal-title":"J Pediatr"},{"key":"key20160301161136741_ref1-bib147","doi-asserted-by":"publisher","first-page":"e109109","DOI":"10.1371\/journal.pone.0109109","article-title":"Trajectories of HbA1c levels in children and youth with type 1 diabetes","volume":"9","author":"Pinhas-Hamiel","year":"2014","journal-title":"PLOS ONE"},{"key":"key20160301161136741_ref1-bib148","volume-title":"Diabetes (Type 1 and Type 2) in Children and Young People: Diagnosis and Management. NICE Guidelines (NG18)","author":"National Institute for Health and Care Excellence"},{"key":"key20160301161136741_ref1-bib149","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2337\/dc11-1746","article-title":"A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to < 10 years","volume":"35","author":"Mauras","year":"2012","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib150","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.2337\/dc14-0030","article-title":"Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 \u00d7 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS)","volume":"37","author":"Little","year":"2014","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib151","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.2337\/dc09-0108","article-title":"The effect of continuous glucose monitoring in well-controlled type 1 diabetes","volume":"32","author":"Beck","year":"2009","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib152","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [Updated March 2011]","author":"Lefebvre","year":"2011"},{"key":"key20160301161136741_ref1-bib153","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/01.STR.22.3.312","article-title":"Probability of stroke: a risk profile from the Framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"key20160301161136741_ref1-bib154","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1076\/0928-6586(200003)711-2FT013","article-title":"Incidence of and risk factors for cataract among diabetes clinic attenders","volume":"7","author":"Janghorbani","year":"2000","journal-title":"Ophthalmic Epidemiol"},{"key":"key20160301161136741_ref1-bib155","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1212\/WNL.50.1.208","article-title":"Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989","volume":"50","author":"Petty","year":"1998","journal-title":"Neurology"},{"key":"key20160301161136741_ref1-bib156","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant","volume":"341","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"key20160301161136741_ref1-bib157","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ophtha.2008.10.016","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes","volume":"116","author":"Klein","year":"2009","journal-title":"Ophthalmology"},{"key":"key20160301161136741_ref1-bib158","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1681\/ASN.2010040354","article-title":"Risk for ESRD in type 1 diabetes remains high despite renoprotection","volume":"22","author":"Rosolowsky","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"key20160301161136741_ref1-bib159","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1755-3768.2009.01619.x","article-title":"Cataract surgery in a population-based cohort of patients with type 1 diabetes: long-term incidence and risk factors","volume":"89","author":"Grauslund","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"key20160301161136741_ref1-bib160","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0140-6736(11)60471-6","article-title":"Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study","volume":"378","author":"Lind","year":"2011","journal-title":"Lancet"},{"key":"key20160301161136741_ref1-bib161","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2337\/diacare.24.5.909","article-title":"Glycemic control is a predictor of survival for diabetic patients on hemodialysis","volume":"24","author":"Morioka","year":"2001","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib162","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/TP.0b013e3181c6ffa4","article-title":"Glucose control is associated with patient survival in diabetic patients after renal transplantation","volume":"89","author":"Wiesbauer","year":"2010","journal-title":"Transplantation"},{"key":"key20160301161136741_ref1-bib163","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2337\/dc08-1679","article-title":"Pulse pressure and prediction of incident foot ulcers in type 2 diabetes","volume":"32","author":"Monami","year":"2009","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib164","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","article-title":"Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study","volume":"321","author":"Adler","year":"2000","journal-title":"BMJ"},{"key":"key20160301161136741_ref1-bib165","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0735-1097(95)00126-K","article-title":"Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year","volume":"26","author":"Malmberg","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"key20160301161136741_ref1-bib166","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists\u2019 (ATT) Collaboration","year":"2009","journal-title":"Lancet"},{"key":"key20160301161136741_ref1-bib167","doi-asserted-by":"publisher","first-page":"b2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: metaanalysis of randomised controlled trials","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ"},{"key":"key20160301161136741_ref1-bib168","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"key20160301161136741_ref1-bib169","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","author":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators","year":"2000","journal-title":"Lancet"},{"key":"key20160301161136741_ref1-bib170","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/bmj.313.7061.853","article-title":"Sex differences in case fatality before and after admission to hospital after acute cardiac events: analysis of community based coronary heart disease register","volume":"313","author":"Sonke","year":"1996","journal-title":"BMJ"},{"key":"key20160301161136741_ref1-bib171","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists\u2019 Collaboration","year":"1994","journal-title":"BMJ"},{"key":"key20160301161136741_ref1-bib172","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1001\/jama.285.4.430","article-title":"Early statin treatment following acute myocardial infarction and 1-year survival","volume":"285","author":"Stenestrand","year":"2001","journal-title":"JAMA"},{"key":"key20160301161136741_ref1-bib173","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1001\/jama.295.17.2046","article-title":"Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials","volume":"295","author":"Briel","year":"2006","journal-title":"JAMA"},{"key":"key20160301161136741_ref1-bib174","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0735-1097(99)00146-1","article-title":"Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group","volume":"34","author":"Gustafsson","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"key20160301161136741_ref1-bib175","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"key20160301161136741_ref1-bib176","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","journal-title":"Lancet"},{"key":"key20160301161136741_ref1-bib177","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000047700","article-title":"Survival and recurrent strokes in patients with different subtypes of stroke: a fourteen-year follow-up study","volume":"12","author":"Eriksson","year":"2001","journal-title":"Cerebrovasc Dis"},{"key":"key20160301161136741_ref1-bib178","doi-asserted-by":"publisher","first-page":"CD002091","DOI":"10.1002\/14651858.CD002091.pub2","article-title":"Interventions in the management of serum lipids for preventing stroke recurrence","volume":"3","author":"Manktelow","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"key20160301161136741_ref1-bib179","doi-asserted-by":"publisher","first-page":"CD000029","DOI":"10.1002\/14651858.CD000029.pub2","article-title":"Antiplatelet therapy for acute ischaemic stroke","volume":"3","author":"Sandercock","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"key20160301161136741_ref1-bib180","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1212\/01.wnl.0000261914.18101.60","article-title":"Is prestroke use of angiotensin-converting enzyme inhibitors associated with better outcome?","volume":"68","author":"Chitravas","year":"2007","journal-title":"Neurology"},{"key":"key20160301161136741_ref1-bib181","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1161\/STROKEAHA.110.580209","article-title":"Ischemic stroke and secondary prevention in clinical practice: a cohort study of 14,529 patients in the Swedish Stroke Register","volume":"41","author":"Asberg","year":"2010","journal-title":"Stroke"},{"key":"key20160301161136741_ref1-bib182","first-page":"1169","article-title":"Drug therapy for chronic heart failure due to left ventricular systolic dysfunction: a review. III. Angiotensin-converting enzyme inhibitors","volume":"27","author":"Ascen\u00e7\u00e3o","year":"2008","journal-title":"Rev Port Cardiol"},{"key":"key20160301161136741_ref1-bib183","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/01.CIR.88.1.107","article-title":"Survival after the onset of congestive heart failure in Framingham Heart Study subjects","volume":"88","author":"Ho","year":"1993","journal-title":"Circulation"},{"key":"key20160301161136741_ref1-bib184","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0140-6736(97)06209-0","article-title":"Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus","volume":"351","author":"Chaturvedi","year":"1998","journal-title":"Lancet"},{"key":"key20160301161136741_ref1-bib185","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.2337\/diabetes.47.9.1507","article-title":"Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM","volume":"47","author":"Penno","year":"1998","journal-title":"Diabetes"},{"key":"key20160301161136741_ref1-bib186","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"key20160301161136741_ref1-bib187","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1046\/j.1445-5994.2002.00255.x","article-title":"Influence of age on the presentation and outcome of acidotic and hyperosmolar diabetic emergencies","volume":"32","author":"MacIsaac","year":"2002","journal-title":"Intern Med J"},{"key":"key20160301161136741_ref1-bib188","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1046\/j.1524-4733.2000.36027.x","article-title":"The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data","volume":"3","author":"Persson","year":"2000","journal-title":"Value Health"},{"key":"key20160301161136741_ref1-bib189","doi-asserted-by":"publisher","DOI":"10.3402\/dfa.v3i0.12169","article-title":"Incidence of re-amputation following partial first ray amputation associated with diabetes mellitus and peripheral sensory neuropathy: a systematic review","volume":"3","author":"Borkosky","year":"2012","journal-title":"Diabet Foot Ankle"},{"key":"key20160301161136741_ref1-bib190","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s001250100013","article-title":"Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations","volume":"44","author":"Ragnarson Tennvall","year":"2001","journal-title":"Diabetologia"},{"key":"key20160301161136741_ref1-bib191","doi-asserted-by":"publisher","first-page":"133945","DOI":"10.2337\/diacare.28.6.1339","article-title":"Depression and all-cause and coronary heart disease mortality among adults with and without diabetes","volume":"28","author":"Egede","year":"2005","journal-title":"Diabetes Care"},{"key":"key20160301161136741_ref1-bib192","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1440-1819.2008.01889.x","article-title":"Neuropathy is associated with depression independently of health-related quality of life in Japanese patients with diabetes","volume":"63","author":"Yoshida","year":"2009","journal-title":"Psychiatry Clin Neurosci"},{"key":"key20160301161136741_ref1-bib193","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/j.1532-5415.2004.52217.x","article-title":"Depression after stroke: a prospective epidemiological study","volume":"52","author":"Whyte","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"key20160301161136741_ref1-bib194","volume-title":"USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States","author":"United States Renal Data System","year":"2010"},{"key":"key20160301161136741_ref1-bib195","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1001\/jama.299.23.2751","article-title":"Examining a bidirectional association between depressive symptoms and diabetes","volume":"299","author":"Golden","year":"2008","journal-title":"JAMA"},{"key":"key20160301161136741_ref1-bib196","doi-asserted-by":"publisher","first-page":"345","DOI":"10.7326\/0003-4819-134-5-200103060-00007","article-title":"The cost-utility of screening for depression in primary care","volume":"134","author":"Valenstein","year":"2001","journal-title":"Ann Intern Med"},{"key":"key20160301161136741_ref1-bib197","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hec.910","article-title":"Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data","volume":"14","author":"Bagust","year":"2005","journal-title":"Health Econ"},{"key":"key20160301161136741_ref1-bib198","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1159\/000177131","article-title":"Mortality, place and mode of death and reinfarction during a period of 5 years after acute myocardial infarction in diabetic and non-diabetic patients","volume":"87","author":"Herlitz","year":"1996","journal-title":"Cardiology"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20170\/hta20170.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20170\/hta20170.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2003398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T11:48:15Z","timestamp":1692100095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta20170\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":198,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2016,2]]}},"alternative-id":["10.3310\/hta20170"],"URL":"https:\/\/doi.org\/10.3310\/hta20170","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}